AR056487A1 - UN MÉTODO PARA TRATAR O ALIVIAR UN NEOPLASMA EN UN MAMIFERO QUE SUFRE DICHO NEOPLASMA MEDIANTE LA ADMINISTRACIoN DE UN VIRUS ONCOLíTICO O UN VECTOR DE TERAPIA GÉNICA - Google Patents

UN MÉTODO PARA TRATAR O ALIVIAR UN NEOPLASMA EN UN MAMIFERO QUE SUFRE DICHO NEOPLASMA MEDIANTE LA ADMINISTRACIoN DE UN VIRUS ONCOLíTICO O UN VECTOR DE TERAPIA GÉNICA

Info

Publication number
AR056487A1
AR056487A1 ARP060103826A ARP060103826A AR056487A1 AR 056487 A1 AR056487 A1 AR 056487A1 AR P060103826 A ARP060103826 A AR P060103826A AR P060103826 A ARP060103826 A AR P060103826A AR 056487 A1 AR056487 A1 AR 056487A1
Authority
AR
Argentina
Prior art keywords
neoplasm
treat
virus
oncolitical
mammer
Prior art date
Application number
ARP060103826A
Other languages
English (en)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of AR056487A1 publication Critical patent/AR056487A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Para tratar o aliviar neoplasmas, y mejorar la eficacia de virus oncolíticos, que comprenden administrarle un virus oncolítico a un mamífero que sufre un neoplasma, y subsiguientemente administrarle un inmunoestimulante, también se proveen métodos para incrementar el reconocimiento inmune de células neoplásticas.
ARP060103826A 2005-08-31 2006-08-31 UN MÉTODO PARA TRATAR O ALIVIAR UN NEOPLASMA EN UN MAMIFERO QUE SUFRE DICHO NEOPLASMA MEDIANTE LA ADMINISTRACIoN DE UN VIRUS ONCOLíTICO O UN VECTOR DE TERAPIA GÉNICA AR056487A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71328705P 2005-08-31 2005-08-31

Publications (1)

Publication Number Publication Date
AR056487A1 true AR056487A1 (es) 2007-10-10

Family

ID=37808428

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103826A AR056487A1 (es) 2005-08-31 2006-08-31 UN MÉTODO PARA TRATAR O ALIVIAR UN NEOPLASMA EN UN MAMIFERO QUE SUFRE DICHO NEOPLASMA MEDIANTE LA ADMINISTRACIoN DE UN VIRUS ONCOLíTICO O UN VECTOR DE TERAPIA GÉNICA

Country Status (13)

Country Link
US (1) US20070071723A1 (es)
EP (1) EP1922085A4 (es)
JP (1) JP2009504687A (es)
CN (1) CN101304761A (es)
AR (1) AR056487A1 (es)
AU (1) AU2006287052B2 (es)
CA (2) CA2825762A1 (es)
IL (1) IL188816A0 (es)
MX (1) MX2008002743A (es)
SG (1) SG149870A1 (es)
TW (1) TW200812614A (es)
WO (1) WO2007025365A1 (es)
ZA (1) ZA200800246B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
GB0720624D0 (en) * 2007-10-20 2007-11-28 Academisch Ziekenhuis Leiden Viral Modification
WO2009135614A2 (en) * 2008-05-09 2009-11-12 Bayer Schering Pharma Aktiengesellschaft Use of a virus regimen for the treatment of diseases
EP2408473B1 (en) 2009-03-16 2016-03-16 McMaster University Vaccination methods
US20100297072A1 (en) * 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
US9352006B2 (en) 2010-10-20 2016-05-31 Icahn School Of Medicine At Mount Sinai Methods and compositions for treating tumors using myeloid derived suppressor cells
CN108125989A (zh) * 2011-04-12 2018-06-08 英特维特国际股份有限公司 溶瘤作用中的禽偏肺病毒
CN104427992B (zh) 2012-01-25 2017-12-19 德那翠丝有限公司 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法
AU2013204555A1 (en) * 2012-04-30 2013-11-14 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
CN105658790A (zh) 2013-02-21 2016-06-08 东安大略研究所儿童医院有限公司 疫苗组合物
JP6857498B2 (ja) * 2014-02-27 2021-04-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための併用方法
MX2017009272A (es) * 2015-01-16 2018-04-11 Anticuerpos que penetran en células.
GB201504251D0 (en) 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CN108338994A (zh) * 2017-01-25 2018-07-31 杭州康万达医药科技有限公司 溶瘤病毒作为用于***和/或癌症的免疫刺激剂的应用
CA3138657A1 (en) * 2019-05-09 2020-11-12 Sator Therapeutics LLC Delivery of oncolytic viruses using dendritic cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275873A1 (en) * 2004-04-29 2007-11-29 Heidner Hans W Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting

Also Published As

Publication number Publication date
CN101304761A (zh) 2008-11-12
SG149870A1 (en) 2009-02-27
AU2006287052B2 (en) 2009-03-12
WO2007025365A1 (en) 2007-03-08
CA2825762A1 (en) 2007-03-08
JP2009504687A (ja) 2009-02-05
IL188816A0 (en) 2008-08-07
EP1922085A4 (en) 2009-12-30
TW200812614A (en) 2008-03-16
EP1922085A1 (en) 2008-05-21
CA2621127A1 (en) 2007-03-08
CA2621127C (en) 2014-02-25
AU2006287052A1 (en) 2007-03-08
ZA200800246B (en) 2009-08-26
US20070071723A1 (en) 2007-03-29
MX2008002743A (es) 2008-03-26

Similar Documents

Publication Publication Date Title
AR056487A1 (es) UN MÉTODO PARA TRATAR O ALIVIAR UN NEOPLASMA EN UN MAMIFERO QUE SUFRE DICHO NEOPLASMA MEDIANTE LA ADMINISTRACIoN DE UN VIRUS ONCOLíTICO O UN VECTOR DE TERAPIA GÉNICA
EP4286009A3 (en) Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
AR059482A1 (es) Uso de supresion inmune local para potenciar terapia viral oncolitica
MX2018003824A (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control.
NZ767596A (en) Antibodies that bind cd39 and uses thereof
EA201891904A1 (ru) Smc комбинированная терапия для лечения злокачественного новообразования
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
NO20072733L (no) Doseformer
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2019000286A (es) Una combinación farmacéutica y método para la regulación del microentorno tumoral e inmunoterapia.
EP4197551A3 (en) Adoptive cell transfer and oncolytic virus combination therapy
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
DK1755659T3 (da) Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
MX2019015194A (es) Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas.
MX2018003757A (es) Composiciones y metodos para producir celulas dendriticas.
BR112014023572A2 (pt) método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
CO2021011034A2 (es) Métodos para tratar el mieloma múltiple
MX2020001451A (es) Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico.
EP3858369A4 (en) CANCER THERAPY IN WHICH AN ONCOLYTIC VACCINE VIRUS AND AN IMMUNE CHECKPOINT INHIBITOR ARE USED IN COMBINATION, AND COMBINED PHARMACEUTICAL COMPOSITION AND MEDICINE USED THEREOF
WO2019204332A3 (en) Pak4 inhibitors and methods of use
WO2019168897A3 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents

Legal Events

Date Code Title Description
FB Suspension of granting procedure